Through a pooled short hairpin RNA (shRNA) screen in human NSCLC cells carrying BRAF V600E mutations, YAP was defined to act as a parallel survival input to promote resistance to BRAF and MEK inhibition by transcriptionally upregulating the expression of anti-apoptotic protein, Bcl-xL [76] (Table 1). The gene discussed is YAP1; the disease is non-small cell lung carcinoma.